Niels M R van der Sangen
Overview
Explore the profile of Niels M R van der Sangen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
85
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van den Broek W, Azzahhafi J, Chan Pin Yin D, van der Sangen N, Sivanesan S, Dijksman L, et al.
Eur Heart J Cardiovasc Pharmacother
. 2024 Nov;
PMID: 39537191
Aims: A genotype-guided P2Y12-inhibitor de-escalation strategy, switching acute coronary syndrome (ACS) patients without a CYP2C19 loss-of-function allele from ticagrelor or prasugrel to clopidogrel, has shown to reduce bleeding risk without...
2.
van der Sangen N, Azzahhafi J, Chan Pin Yin D, Zaaijer L, van den Broek W, Walhout R, et al.
Thromb Haemost
. 2024 Oct;
PMID: 39471977
Aims: Patients presenting with acute coronary syndrome (ACS) are frequently treated with the P2Y-inhibitor ticagrelor. Some patients prematurely discontinue ticagrelor, but the incidence of reasons for and clinical implications of...
3.
Azzahhafi J, van den Broek W, Chan Pin Yin D, van der Sangen N, Sivanesan S, Bofarid S, et al.
JACC Cardiovasc Interv
. 2024 Sep;
PMID: 39217531
Background: CYP2C19 genotype-guided de-escalation from ticagrelor or prasugrel to clopidogrel may optimize the balance between ischemic and bleeding risk in patients with acute coronary syndrome (ACS). Objectives: This study sought...
4.
Bor W, Azzahhafi J, Maio N, van der Sangen N, Verburg A, Rayhi S, et al.
EuroIntervention
. 2024 Aug;
20(16):996-1007.
PMID: 39155759
Background: Acute coronary syndrome (ACS) is frequently accompanied by newly diagnosed atrial fibrillation (AF). Aims: We aimed to compare the risk of major adverse cardiovascular events (MACE) in ACS patients...
5.
van der Sangen N, Claessen B, Kucuk I, den Hartog A, Kikkert W, Appelman Y, et al.
Eur Heart J Open
. 2023 Sep;
3(5):oead075.
PMID: 37680589
Graphical AbstractClinical outcomes and treatment adherence during 12 months follow-up. *Second bleeding event in same patient. PCI, percutaneous coronary intervention; TVR, target vessel revascularization.
6.
van der Sangen N, Henriques J
Neth Heart J
. 2023 Aug;
31(9):330-333.
PMID: 37540404
No abstract available.
7.
van der Sangen N, Azzahhafi J, Chan Pin Yin D, Rayhi S, van Weede V, Walhout R, et al.
Open Heart
. 2023 Aug;
10(2).
PMID: 37527905
Objective: Patients with acute coronary syndrome (ACS) remain at high risk for recurrent ischaemic and bleeding events during follow-up. Our study aimed to quantify and compare the impact of these...
8.
van der Sangen N, Kucuk I, Sivanesan S, Appelman Y, Ten Berg J, Verburg A, et al.
Am Heart J
. 2023 Jul;
265:114-120.
PMID: 37517430
Background: Early aspirin withdrawal, also known as P2Y-inhibitor monotherapy, following percutaneous coronary intervention (PCI) for non-ST-segment elevation acute coronary syndrome (NSTE-ACS) can reduce bleeding without a trade-off in efficacy. Still...
9.
van der Sangen N, Claessen B
Am J Cardiol
. 2023 Jul;
201:362-363.
PMID: 37423809
No abstract available.
10.
de Ritter R, Sep S, van Greevenbroek M, Kusters Y, Vos R, Bots M, et al.
Diabetologia
. 2023 Feb;
66(5):861-872.
PMID: 36805778
Aims/hypothesis: Obesity is a major risk factor for type 2 diabetes. However, body composition differs between women and men. In this study we investigate the association between diabetes status and...